实用肝脏病杂志 ›› 2010, Vol. 13 ›› Issue (4): 272-274.doi: 10.3969/j.issn.1672-5069.2010.04.011

• 论著 • 上一篇    下一篇

自体骨髓干细胞治疗失代偿期肝硬化患者50例疗效观察*

王方,张小岗,张静,周一鸣,印建国,云升浩,冯雪梅,周新人,黄涛   

  1. 730070兰州市 兰州军区总医院安宁分院感染病科(王方,张静,云升浩,冯雪梅,周新人,黄涛);
    放射科(印建国);
    甘肃省中医院骨科(张小岗);
    北京军区总医院肝病科(周一鸣)
  • 收稿日期:2009-11-12 出版日期:2010-08-10 发布日期:2016-04-18
  • 作者简介:王方 女,40岁,医学博士,副主任医师。主要研究方向为慢性肝病的发病机理和治疗。E-mail:kaixin919@163.com
  • 基金资助:
    甘肃省自然科学基金项目(编号:3ZS061-A25-090);甘肃省科技支撑项目(编号:2007GS04524)

The curative effect of auto-marrow stem cells in treatment fo 50 patients with decompensated liver cirrhosis

ANG Fang,ZHANG Xiaogang,ZHANG Jing,et al.   

  1. Department of Infectious Diseases,General Hospital of PLA,Lanzhou Military Area Commard,Lanzhou 730070,China
  • Received:2009-11-12 Online:2010-08-10 Published:2016-04-18

摘要: 目的 探讨自体骨髓干细胞治疗失代偿期肝硬化患者的安全性及对肝功能的改善作用。方法 选择失代偿期肝硬化患者97例,随机分为治疗组50例和对照组47例,对照组行保守治疗,治疗组在保守治疗的基础上行自体骨髓干细胞治疗。结果 治疗后第3天全部患者乏力、纳差症状改善,而对照组只有2例(4.2%)改善,两组间差异有显著性(P<0.05);治疗后8wk治疗组腹水消退24例(44%),腹胀减轻45例(90%),而对照组分别为2例(4.2%)和 7例(14.9%),差异具有显著性;治疗后8wk,治疗组和对照组血清ALB水平分别为33.1±8.3g/L和25.6±7.6g/L,具有显著性差异(P<0.05),两组PTA分别为43.0±11.4%和38.2±12.5%,差异有显著性(P<0.05);2例治疗组患者在治疗后第2天出现低热,余未发现严重的不良反应及并发症。结论 自体骨髓干细胞治疗失代偿期肝硬化患者有一定的疗效及安全性。

关键词: 失代偿期肝硬化, 自体骨髓干细胞, 细胞治疗

Abstract: Objective This study aims to observe the curative effect and safety of auto-marrow stem cells in treatment of patients with decompensated liver cirrhosis. Methods 97 cases with decompensated liver cirrhosis were randomly divided into control group(with conventional therapy)and therapy group(with treatment of auto-marrow stem cells on the base of conventional therapy). The clinical effectiveness,blood biochemical index and adverse events after 1,2,3,4,8 weeks were observed. Results All patients in therapy group had obviously their improvement in clinical symptoms after treatment,while only 4.2% patients improved in control group;The level of albumin after 8 weeks was 33.1±8.3g/L in study group,much higher than 25.6±7.6g/L in control group(P<0.05);The prothrombin time activity were 43.0±11.4% and 38.2±12.5% in the two groups,respectively(P<0.05);The TBIL were 38.3±12.2 μmol/L and 40.6±13.3 μmol/L,respectively(P>0.05);The level of AFP, leukocyte and platelet counts had no difference between the two groups. Conclusion The curative effect of auto-marrow stem cells in treatment of patients with decompensated liver cirrhosis is safe and effective.

Key words: Decompensated liver cirrhosis, Auto-marrow stem cells, Cell treatment